Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2005

View Archived Issues

Immune modulation therapy with Celacade benefits heart failure patients

Oral pimecrolimus reported effective in moderate to severe atopic dermatitis

Patupilone activity, safety gauged in phase I/II trial in non-small cell lung cancer

OGX-011 reported to be well tolerated when added to NSCLC chemotherapy

Malignant pleural mesothelioma patients achieve disease control with vinflunine

Caspase inhibitor prevents plaque progression in atherosclerotic mice

Novel adenosine A3 receptor antagonists reported

NO moiety in statins improves their therapeutic potential

Priority review for Exjade in Canada

SPA agreement for phase III study of renzapride for c-IBS

7TM Pharma begins phase I/II trials for TM-30338 for obesity

Astex Technology changes name to Astex Therapeutics

Albany Molecular Research partners with NINDS in spinal muscular atrophy

Tracleer study shows benefit in Eisenmenger's syndrome

Phase IIIb/IV ASSENT 4 PCI study of tenecteplase stopped early

MVA smallpox vaccine MVA-3000 begins phase II trial

Pagoclone studied in phase II trial for persistent developmental stuttering

Triglide launched in U.S.

VNS Therapy System receives FDA approval for treatment-resistant depression

Thelin NDA receives March 2006 action date

MATCHED study of MC-4232 completes treatment period

Novartis to acquire Bristol-Myers Squibb's OTC portfolio

Prous Science announces publication of a comprehensive review on Behcet's disease

NMP22 BladderChek Test approved in Japan

Recent patents cover therapeutic agents for cognitive impairment and neurodegeneration

Novel antithrombotic agents reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...